ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.26
0.00%
US Tech 100
19,886.40
0.20%
S&P 500
5,631.22
0.28%
US Dollar vs CAD
1.36835
0.04%
Bitcoin
63,659.87
-1.84%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alzamend Neuro Inc (ALZN)

  7. Alzamend Neuro Inc (ALZN) News

ALZN

Alzamend Neuro (ALZN)

Alzamend Neuro Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALZN
DateTimeSourceHeadlineSymbolCompany
12/20/20213:16AMTipRanksUnivest Securities Reaffirms Their Buy Rating on Alzamend Neuro (ALZN)NASDAQ:ALZNAlzamend Neuro Inc
12/17/20213:31PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
12/17/20218:00AMBusiness WireAlzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’sNASDAQ:ALZNAlzamend Neuro Inc
12/16/20214:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
12/14/202112:06PMTipRanksUnivest Securities Thinks Alzamend Neuro’s Stock is Going to RecoverNASDAQ:ALZNAlzamend Neuro Inc
12/13/20212:58PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALZNAlzamend Neuro Inc
11/30/20217:30AMBusiness WireAlzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’sNASDAQ:ALZNAlzamend Neuro Inc
11/22/20213:04AMTipRanksUnivest Securities Thinks Alzamend Neuro’s Stock is Going to RecoverNASDAQ:ALZNAlzamend Neuro Inc
11/10/20214:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
11/08/20214:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
11/04/20214:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
10/18/20214:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
10/18/20214:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
10/18/20214:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
10/18/20214:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
09/30/20213:31PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
09/30/20219:11AMBusiness WireAlzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s DiseaseNASDAQ:ALZNAlzamend Neuro Inc
09/16/20215:30PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
09/15/20214:08PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
09/15/20214:08PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
09/15/20214:08PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
09/13/20213:18PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALZNAlzamend Neuro Inc
09/13/20215:30AMBusiness WireAlzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s DiseaseNASDAQ:ALZNAlzamend Neuro Inc
09/03/20214:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
08/19/20215:33PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
08/17/20217:00AMBusiness WireAlzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021NASDAQ:ALZNAlzamend Neuro Inc
08/13/20214:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
08/10/20215:17PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALZNAlzamend Neuro Inc
08/04/20218:36AMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ALZNAlzamend Neuro Inc
08/04/20215:30AMBusiness WireAlzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power LendingNASDAQ:ALZNAlzamend Neuro Inc
 Showing the most relevant articles for your search:NASDAQ:ALZN

Your Recent History

USOTC
AXXA
Exxe (PK)
USOTC
MGON
Megola (PK)
NASDAQ
FFIE
Faraday Future Intellige...
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
RONN
Ronn Motor (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
BLEG
Branded Legacy (PK)
USOTC
GRST
Ethema Health (PK)
USOTC
WDLF
Decentral Life (PK)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
ENZC
Enzolytics (PK)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
HIRU
Hiru (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
IFUS
Impact Fusion (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved